[Federal Register Volume 81, Number 145 (Thursday, July 28, 2016)]
[Notices]
[Pages 49664-49669]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-17848]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-0007]
Animal Drug User Fee Rates and Payment Procedures for Fiscal Year
2017
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the rates
and payment procedures for fiscal year (FY) 2017 animal drug user fees.
The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by
the Animal Drug User Fee Amendments of 2013 (ADUFA III), authorizes FDA
to collect user fees for certain animal drug applications and
supplements, for certain animal drug products, for certain
establishments where such products are made, and for certain sponsors
of such animal drug applications and/or investigational animal drug
submissions. This notice establishes the fee rates for FY 2017.
FOR FURTHER INFORMATION CONTACT: Visit FDA's Web site at http://www.fda.gov/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/default.htm
or contact Lisa Kable, Center for Veterinary Medicine (HFV-10), Food
and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-
402-6888. For general questions, you may also email the Center for
Veterinary Medicine (CVM) at: [email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Section 740 of the FD&C Act (21 U.S.C. 379j-12) establishes four
different types of user fees: (1) Fees for certain types of animal drug
applications and supplements; (2) annual fees for certain animal drug
products; (3) annual fees for certain establishments where such
products are made; and (4) annual fees for certain sponsors of animal
drug applications and/or investigational animal drug submissions (21
U.S.C. 379j-12(a)). When certain conditions are met, FDA will waive or
reduce fees (21 U.S.C. 379j-12(d)).
For FY 2014 through FY 2018, the FD&C Act establishes aggregate
yearly base revenue amounts for each fiscal year (21 U.S.C. 379j-
12(b)(1)). Base revenue amounts established for years after FY 2014 are
subject to adjustment for inflation and workload (21 U.S.C. 379j-
12(c)). Fees for applications, establishments, products, and sponsors
are to be established each year by FDA so that the percentages of the
total revenue that are derived from each type of user fee will be as
follows: Revenue from application fees shall be 20 percent of total fee
revenue; revenue from product fees shall be 27 percent of total fee
revenue; revenue from establishment fees shall be 26 percent of total
fee revenue; and revenue from sponsor fees shall be 27 percent of total
fee revenue (21 U.S.C. 379j-12(b)(2)).
For FY 2017, the animal drug user fee rates are: $350,700 for an
animal drug application; $175,350 for a supplemental animal drug
application for which safety or effectiveness data are required and for
an animal drug application subject to the criteria set forth in section
512(d)(4) of the FD&C Act (21 U.S.C. 360b(d)(4)); $8,195 for an annual
product fee; $111,900 for an annual establishment fee; and $103,100 for
an annual sponsor fee. FDA will issue invoices for FY 2017 product,
establishment, and sponsor fees by December 31, 2016, and payment will
be due by January 31, 2017. The application fee rates are effective for
applications submitted on or after October 1, 2016, and will remain in
effect through September 30, 2017. Applications will not be accepted
for review until FDA has received full payment of application fees and
any other animal drug user fees owed under the Animal Drug User Fee
program (ADUFA program).
II. Revenue Amount for FY 2017
A. Statutory Fee Revenue Amounts
ADUFA III, Title I of Public Law 113-14, specifies that the
aggregate fee revenue amount for FY 2017 for all animal drug user fee
categories is $21,600,000 (21 U.S.C. 379j-12(b)(1)(B).).
B. Inflation Adjustment to Fee Revenue Amount
The fee revenue amount established in ADUFA III for FY 2015 and
subsequent fiscal years are subject to an inflation adjustment (21
U.S.C. 379j-12(c)(2)).
The component of the inflation adjustment for payroll costs shall
be one plus the average annual percent change in the cost of all
personnel compensation and benefits (PC&B) paid per full-time
equivalent position (FTE) at FDA for the first three of the four
preceding fiscal years, multiplied by the proportion of PC&B costs to
total FDA costs for the first three of the four preceding fiscal years
(see 21 U.S.C. 379j-12(c)(2)(A) and (B)). The data on total PC&B paid
and numbers of FTE paid, from which the average cost per FTE can be
derived, are published in FDA's Justification of Estimates for
Appropriations Committees.
Table 1 summarizes that actual cost and FTE data for the specified
fiscal years, and provides the percent change from the previous fiscal
year and the average percent change over the first three of the four
fiscal years preceding FY 2017. The 3-year average is 1.8759 percent.
[[Page 49665]]
Table 1--FDA Personnel Compensation and Benefits (PC&B) Each Year and Percent Change
--------------------------------------------------------------------------------------------------------------------------------------------------------
Fiscal year 2013 2014 2015 3-year average
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total PC&B................................................... $1,927,703,000 $2,054,937,000 $2,232,304,000 ..............
Total FTE.................................................... 13,974 14,555 15,484 ..............
PC&B per FTE................................................. 137,949 141,184 144,168 ..............
Percent Change from Previous Year............................ 1.1690% 2.3451% 2.1136% 1.8759%
--------------------------------------------------------------------------------------------------------------------------------------------------------
The statute specifies that this 1.8759 percent should be multiplied
by the proportion of PC&B costs to total FDA costs. Table 2 shows the
amount of PC&B and the total amount obligated by FDA for the same 3
FYs.
Table 2--PC&B as a Percent of Total Costs at FDA
--------------------------------------------------------------------------------------------------------------------------------------------------------
Fiscal year 2013 2014 2015 3-year average
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total PC&B................................................... $1,927,703,000 $2,054,937,000 $2,232,304,000 ..............
Total Costs.................................................. 4,151,343,000 4,298,476,000 4,510,565,000 ..............
PC&B Percent................................................. 46.4356% 47.8062% 49.4906% 47.9108%
--------------------------------------------------------------------------------------------------------------------------------------------------------
The payroll adjustment is 1.8759 percent multiplied by 47.9108
percent (or 0.8988 percent).
The statute specifies that the portion of the inflation adjustment
for non-payroll costs for FY 2017 is the average annual percent change
that occurred in the Consumer Price Index (CPI) for urban consumers
(Washington-Baltimore, DC-MD-VA-WV; not seasonally adjusted; all items
less food and energy; annual index) for the first 3 of the preceding 4
years of available data multiplied by the proportion of all costs other
than PC&B costs to total FDA costs (see 21 U.S.C. 379j-12(c)(2)(C)).
Table 3 provides the summary data for the percent change in the
specified CPI for the Baltimore-Washington area. The data from the
Bureau of Labor Statistics is shown in table 3.
Table 3--Annual and 3-Year Average Percent Change in Baltimore-Washington Area CPI Less Food and Energy
--------------------------------------------------------------------------------------------------------------------------------------------------------
Year 2013 2014 2015 3-year average
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annual CPI................................................... 146.953 149.581 152.242 ..............
Annual Percent Change........................................ 1.7588% 1.7883% 1.7790% 1.7754%
--------------------------------------------------------------------------------------------------------------------------------------------------------
To calculate the inflation adjustment for non-pay costs, we
multiply the 1.7754 percent by the proportion of all costs other than
PC&B to total FDA costs. Since 47.9108 percent was obligated for PC&B
as shown in table 2, 52.0892 percent is the portion of costs other than
PC&B (100 percent minus 47.9108 percent equals 52.0892 percent). The
non-payroll adjustment is 1.7754 percent times 52.0892 percent, or
0.9248 percent.
Next, we add the payroll component (0.8988 percent) to the non-pay
component (0.9248 percent), for a total inflation adjustment of 1.8236
percent for FY 2017.
ADUFA III provides for the inflation adjustment to be compounded
each fiscal year after FY 2014 (see 21 U.S.C. 379j-12(c)(2)). The
factor for FY 2017 (1.8236 percent) is compounded by adding 1 and then
multiplying by 1 plus the inflation adjustment factor for FY 2016
(2.1121 percent), as published in the Federal Register of August 3,
2015 (80 FR 45993 to 45998), which equals 1.060746 (rounded) (1.018236
times 1.041749) for FY 2017. We then multiply the base revenue amount
for FY 2017 ($21,600,000) by 1.060746, yielding an inflation adjusted
amount of $22,912,114.
C. Workload Adjustment to Inflation Adjusted Fee Revenue Amount
A workload adjustment will be calculated to the inflation adjusted
fee revenue amount established in ADUFA III for FY 2015 and subsequent
fiscal years (21 U.S.C. 379j-12(c)(3)).
FDA calculated the average number of each of the five types of
applications and submissions specified in the workload adjustment
provision (animal drug applications, supplemental animal drug
applications for which data with respect to safety or efficacy are
required, manufacturing supplemental animal drug applications,
investigational animal drug study submissions, and investigational
animal drug protocol submissions) received over the 5-year period that
ended on September 30, 2013 (the base years), and the average number of
each of these types of applications and submissions over the most
recent 5-year period that ended June 30, 2016.
The results of these calculations are presented in the first two
columns of table 4. Column 3 reflects the percent change in workload
over the two 5-year periods. Column 4 shows the weighting factor for
each type of application, reflecting how much of the total FDA animal
drug review workload was accounted for by each type of application or
submission in the table during the most recent five years. Column 5 is
the weighted percent change in each category of workload, and was
derived by multiplying the weighting factor in each line in column 4 by
the percent change from the base years in column 3. At the bottom right
of table 4 the sum of the values in column 5 is added, reflecting a
total change in workload of 3.3206 percent for FY 2017. This is the
workload adjuster for FY 2017.
[[Page 49666]]
Table 4--Workload Adjuster Calculation
[Numbers may not add due to rounding]
----------------------------------------------------------------------------------------------------------------
Column 1 Column 2 Column 3 Column 4 Column 5
-------------------------------------------------------------------------------
Application type 5-year average Latest 5-year Weighting Weighted
(base years) average Percent change factor percent change
----------------------------------------------------------------------------------------------------------------
New Animal Drug Applications 9.8000 13.4000 36.7347 0.0250 0.9168
(NADAs)........................
Supplemental NADAs with Safety 9.6000 12.4000 29.1667 0.0342 0.9971
or Efficacy Data...............
Manufacturing Supplements....... 361.0000 324.6000 -10.0831 0.1565 -1.5783
Investigational Study 216.4000 204.6000 -5.4529 0.6002 -3.2727
Submissions....................
Investigational Protocol 133.6000 179.0000 33.9820 0.1841 6.2577
Submissions....................
-------------------------------------------------------------------------------
FY 2017 Workload Adjuster... .............. .............. .............. .............. 3.3206
----------------------------------------------------------------------------------------------------------------
FDA experienced an increase in the number of new animal drug
applications (NADAs) and supplemental NADAs with safety or
effectiveness data. Over the last several years FDA has seen an
increase in the number of animal drug products brought by animal drug
sponsors for review in the drug evaluation process. These new animal
drug products come from both existing animal drug sponsors as well as
sponsors new to the animal drug market. The increase in new animal drug
products have contributed to an increase in the number of protocol
submissions and NADAs submitted for many novel drug classes and novel
indications for both food-producing animals and companion animals. FDA
can expect that the increases in reviewed protocols will lead in the
near future to an increase in the number of Investigational Study
Submissions and NADAs or supplemental NADAs as sponsors work their
products through the regulatory review process. Additionally, FDA has
seen an increase in the number of animal drug sponsors pursuing
multiple changes to their existing NADAs (e.g., new indications, new
species, changes in dosage). For this reason we are seeing an increase
in the number of supplemental NADAs with safety or effectiveness data.
As a result, the statutory revenue amount after the inflation
adjustment ($22,912,114) must now be increased by 3.3206 percent to
reflect the changes in review workload (workload adjustment), for a
total fee revenue target of $23,673,000 (rounded to the nearest
thousand dollars).
D. FY 2017 Fee Revenue Amounts
ADUFA III specifies that the revenue amount of $23,673,000 for FY
2017 is to be divided as follows: 20 percent, or a total of $4,734,000
(rounded to the nearest thousand dollars), is to come from application
fees; 27 percent, or a total of $6,392,000 (rounded to the nearest
thousand dollars), is to come from product fees; 26 percent, or a total
of $6,155,000 (rounded to the nearest thousand dollars), is to come
from establishment fees; and 27 percent, or a total of $6,392,000
(rounded to the nearest thousand dollars), is to come from sponsor fees
(21 U.S.C. 379j-12(b)).
III. Application Fee Calculations for FY 2017
A. Application Fee Revenues and Numbers of Fee-Paying Applications
Each person that submits an animal drug application or a
supplemental animal drug application shall be subject to an application
fee, with limited exceptions (see 21 U.S.C. 379j-12 (a)(1)). The term
``animal drug application'' means an application for approval of any
new animal drug submitted under section 512(b)(1) (21 U.S.C. 379j-
11(1)). A ``supplemental animal drug application'' is defined as a
request to the Secretary to approve a change in an animal drug
application which has been approved, or a request to the Secretary to
approve a change to an application approved under section 512(c)(2) for
which data with respect to safety or effectiveness are required (21
U.S.C. 379j-11(2)). The application fees are to be set so that they
will generate $4,734,000 in fee revenue for FY 2017. The fee for a
supplemental animal drug application for which safety or effectiveness
data are required and for an animal drug application subject to
criteria set forth in section 512(d)(4) of the FD&C Act is to be set at
50 percent of the animal drug application fee (21 U.S.C. 379j-
12(a)(1)(A)(ii)).
To set animal drug application fees and supplemental animal drug
application fees to realize $4,734,000 FDA must first make some
assumptions about the number of fee-paying applications and supplements
the Agency will receive in FY 2017.
The Agency knows the number of applications that have been
submitted in previous years. That number fluctuates from year to year.
In estimating the fee revenue to be generated by animal drug
application fees in FY 2017, FDA is assuming that the number of
applications that will pay fees in FY 2017 will equal the average
number of submissions over the five most recent completed years of the
ADUFA program (FY 2011 to FY 2015). FDA believes that this is a
reasonable approach after 12 completed years of experience with this
program.
Over the five most recent completed years, the average number of
animal drug applications that would have been subject to the full fee
was 7.2. Over this same period, the average number of supplemental
applications and applications subject to the criteria set forth in
section 512(d)(4) of the FD&C Act that would have been subject to half
of the full fee was 12.6.
B. Application Fee Rates for FY 2017
FDA must set the fee rates for FY 2017 so that the estimated 7.2
applications that pay the full fee and the estimated 12.6 supplemental
applications and applications subject to the criteria set forth in
section 512(d)(4) of the FD&C Act that pay half of the full fee will
generate a total of $4,734,000. To generate this amount, the fee for an
animal drug application, rounded to the nearest $100, will have to be
$350,700, and the fee for a supplemental animal drug application for
which safety or effectiveness data are required and for applications
subject to the criteria set forth in section 512(d)(4) of the FD&C Act
will have to be $175,350.
IV. Product Fee Calculations for FY 2017
A. Product Fee Revenues and Numbers of Fee-Paying Products
The animal drug product fee (also referred to as the product fee)
must be paid annually by the person named as the applicant in a new
animal drug
[[Page 49667]]
application or supplemental new animal drug application for an animal
drug product submitted for listing under section 510 of the FD&C Act
(21 U.S.C. 360), and who had an animal drug application or supplemental
animal drug application pending at FDA after September 1, 2003 (21
U.S.C. 379j-12(a)(2)). The term ``animal drug product'' means each
specific strength or potency of a particular active ingredient or
ingredients in final dosage form marketed by a particular manufacturer
or distributor, which is uniquely identified by the labeler code and
product code portions of the national drug code, and for which an
animal drug application or a supplemental animal drug application has
been approved (21 U.S.C. 379j-11(3)). The product fees are to be set so
that they will generate $6,392,000 in fee revenue for FY 2017.
To set animal drug product fees to realize $6,392,000, FDA must
make some assumptions about the number of products for which these fees
will be paid in FY 2017. FDA developed data on all animal drug products
that have been submitted for listing under section 510 of the FD&C Act
and matched this to the list of all persons who had an animal drug
application or supplement pending after September 1, 2003. As of June
2016, FDA estimates that there are a total of 804 products submitted
for listing by persons who had an animal drug application or
supplemental animal drug application pending after September 1, 2003.
Based on this, FDA estimates that a total of 804 products will be
subject to this fee in FY 2017.
In estimating the fee revenue to be generated by animal drug
product fees in FY 2017, FDA is assuming that 3 percent of the products
invoiced, or 24, will not pay fees in FY 2017 due to fee waivers and
reductions. FDA has kept this estimate at 3 percent this year, based on
historical data over the past 5 completed years of the ADUFA program.
Based on experience over the first 12 completed years of the ADUFA
program, FDA believes that this is a reasonable basis for estimating
the number of fee-paying products in FY 2017.
Accordingly, the Agency estimates that a total of 780 (804 minus
24) products will be subject to product fees in FY 2017.
B. Product Fee Rates for FY 2017
FDA must set the fee rates for FY 2017 so that the estimated 780
products that pay fees will generate a total of $6,392,000. To generate
this amount will require the fee for an animal drug product, rounded to
the nearest $5, to be $8,195.
V. Establishment Fee Calculations for FY 2017
A. Establishment Fee Revenues and Numbers of Fee-Paying Establishments
The animal drug establishment fee (also referred to as the
establishment fee) must be paid annually by the person who: (1) Owns or
operates, directly or through an affiliate, an animal drug
establishment; (2) is named as the applicant in an animal drug
application or supplemental animal drug application for an animal drug
product submitted for listing under section 510 of the FD&C Act; (3)
had an animal drug application or supplemental animal drug application
pending at FDA after September 1, 2003; and (4) whose establishment
engaged in the manufacture of the animal drug product during the fiscal
year (see 21 U.S.C. 379j-12(a)(3)). An establishment subject to animal
drug establishment fees is assessed only one such fee per fiscal year.
The term ``animal drug establishment'' is defined as a foreign or
domestic place of business which is at one general physical location
consisting of one or more buildings all of which are within 5 miles of
each other, at which one or more animal drug products are manufactured
in final dosage form (21 U.S.C. 379j-11(4)). The establishment fees are
to be set so that they will generate $6,155,000 in fee revenue for FY
2017.
To set animal drug establishment fees to realize $6,155,000, FDA
must make some assumptions about the number of establishments for which
these fees will be paid in FY 2017. FDA developed data on all animal
drug establishments and matched this to the list of all persons who had
an animal drug application or supplement pending after September 1,
2003. As of June 2016, FDA estimates that there are a total of 62
establishments owned or operated by persons who had an animal drug
application or supplemental animal drug application pending after
September 1, 2003. Based on this, FDA believes that 62 establishments
will be subject to this fee in FY 2017.
In estimating the fee revenue to be generated by animal drug
establishment fees in FY 2017, FDA is assuming that 11 percent of the
establishments invoiced, or seven, will not pay fees in FY 2017 due to
fee waivers and reductions. FDA has reduced this estimate from 12
percent to 11 percent this year, based on historical data over the past
5 completed years. Based on experience over the past 12 completed years
of the ADUFA program, FDA believes that this is a reasonable basis for
estimating the number of fee-paying establishments in FY 2017.
Accordingly, the Agency estimates that a total of 55 establishments
(62 minus 7) will be subject to establishment fees in FY 2017.
B. Establishment Fee Rates for FY 2017
FDA must set the fee rates for FY 2017 so that the estimated 55
establishments that pay fees will generate a total of $6,155,000. To
generate this amount will require the fee for an animal drug
establishment, rounded to the nearest $50, to be $111,900.
VI. Sponsor Fee Calculations for FY 2017
A. Sponsor Fee Revenues and Numbers of Fee-Paying Sponsors
The animal drug sponsor fee (also referred to as the sponsor fee)
must be paid annually by each person who: (1) Is named as the applicant
in an animal drug application, except for an approved application for
which all subject products have been removed from listing under section
510 of the FD&C Act, or has submitted an investigational animal drug
submission that has not been terminated or otherwise rendered inactive
and (2) had an animal drug application, supplemental animal drug
application, or investigational animal drug submission pending at FDA
after September 1, 2003 (see 21 U.S.C. 379j-11(6) and 379j-12(a)(4)).
An animal drug sponsor is subject to only one such fee each fiscal year
(see 21 U.S.C. 379j-12(a)(4)). The sponsor fees are to be set so that
they will generate $6,392,000 in fee revenue for FY 2017.
To set animal drug sponsor fees to realize $6,392,000, FDA must
make some assumptions about the number of sponsors who will pay these
fees in FY 2017. Based on the number of firms that would have met this
definition in each of the past 12 completed years of the ADUFA program,
FDA estimates that a total of 189 sponsors will meet this definition in
FY 2017.
Careful review indicates that 35 percent of these sponsors will
qualify for minor use/minor species waiver or reduction (21 U.S.C.
379j-12(d)(1)(D)). Based on the Agency's experience to date with
sponsor fees, FDA's current best estimate is that an additional 32
percent will qualify for other waivers or reductions, for a total of 67
percent of the sponsors invoiced, or 127, who will not pay fees in FY
2017 due to fee waivers and reductions. FDA has increased this estimate
from 65 percent
[[Page 49668]]
to 67 percent this year, based on historical data over the past 5
completed years of the ADUFA program. FDA believes that this is a
reasonable basis for estimating the number of fee-paying sponsors in FY
2017.
Accordingly, the Agency estimates that a total of 62 sponsors (189
minus 127) will be subject to and pay sponsor fees in FY 2017.
B. Sponsor Fee Rates for FY 2017
FDA must set the fee rates for FY 2017 so that the estimated 62
sponsors that pay fees will generate a total of $6,392,000. To generate
this amount will require the fee for an animal drug sponsor, rounded to
the nearest $50, to be $103,100.
VII. Fee Schedule for FY 2017
The fee rates for FY 2017 are summarized in Table 5.
Table 5--FY 2017 Fee Rates
------------------------------------------------------------------------
Fee rate for
Animal drug user fee category FY 2017 ($)
------------------------------------------------------------------------
Animal Drug Application Fees:
Animal Drug Application............................. 350,700
Supplemental Animal Drug Application for Which 175,350
Safety or Effectiveness Data are Required or Animal
Drug Application Subject to the Criteria Set Forth
in Section 512(d)(4) of the FD&C Act...............
Animal Drug Product Fee............................. 8,195
Animal Drug Establishment Fee \1\................... 111,900
Animal Drug Sponsor Fee \2\......................... 103,100
------------------------------------------------------------------------
\1\ An animal drug establishment is subject to only one such fee each
fiscal year.
\2\ An animal drug sponsor is subject to only one such fee each fiscal
year.
VIII. Procedures for Paying the FY 2017 Fees
A. Application Fees and Payment Instructions
The appropriate application fee established in the new fee schedule
must be paid for an animal drug application or supplement subject to
fees under ADUFA III that is submitted on or after October 1, 2016.
Payment must be made in U.S. currency by check, bank draft, U.S. postal
money order payable to the order of the Food and Drug Administration,
wire transfer, or electronically using Pay.gov. The preferred payment
method is online using electronic check (Automated Clearing House (ACH)
also known as eCheck) or credit card (Discover, VISA, MasterCard,
American Express). Secure electronic payments can be submitted using
the User Fees Payment Portal at https://userfees.fda.gov/pay or the
Pay.gov payment option is available to you after you submit a cover
sheet. Once you search for your invoice, click ``Pay Now'' to be
redirected to Pay.gov. Note that electronic payment options are based
on the balance due. Payment by credit card is available for balances
less than $25,000. If the balance exceeds this amount, only the ACH
option is available. Payments must be drawn on U.S bank accounts as
well as U.S. credit cards.
On your check, bank draft, or U.S. postal money order, please write
your application's unique Payment Identification Number (PIN),
beginning with the letters AD, from the upper right-hand corner of your
completed Animal Drug User Fee Cover Sheet. Also write the FDA post
office box number (P.O. Box 979033) on the enclosed check, bank draft,
or money order. Your payment and a copy of the completed Animal Drug
User Fee Cover Sheet can be mailed to: Food and Drug Administration,
P.O. Box 979033, St. Louis, MO 63197-9000.
If payment is made by wire transfer, send payment to: U.S.
Department of Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045,
FDA Deposit Account Number: 75060099, U.S. Department of Treasury
routing/transit number: 021030004, SWIFT Number: FRNYUS33, Beneficiary:
FDA, 8455 Colesville Rd., 14th Floor, Silver Spring, MD 20993-0002. You
are responsible for any administrative costs associated with the
processing of a wire transfer. Contact your bank or financial
institution about the fee and add it to your payment to ensure that
your fee is fully paid.
If you prefer to send a check by a courier, the courier may deliver
the check and printed copy of the cover sheet to: U.S. Bank, Attn:
Government Lockbox 979033, 1005 Convention Plaza, St. Louis, MO 63101.
(Note: This address is for courier delivery only. If you have any
questions concerning courier delivery contact the U.S. Bank at 314-418-
4013. This telephone number is only for questions about courier
delivery.)
The tax identification number of FDA is 53-0196965. (Note: In no
case should the payment for the fee be submitted to FDA with the
application.)
It is helpful if the fee arrives at the bank at least a day or two
before the application arrives at FDA's CVM. FDA records the official
application receipt date as the later of the following: The date the
application was received by FDA's CVM, or the date U.S. Bank notifies
FDA that your payment in the full amount has been received, or when the
U.S. Treasury notifies FDA of receipt of an electronic or wire transfer
payment. U.S. Bank and the U.S. Treasury are required to notify FDA
within 1 working day, using the PIN described previously.
B. Application Cover Sheet Procedures
Step One--Create a user account and password. Log on to the ADUFA
Web site at http://www.fda.gov/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/default.htm and, under Tools and Resources,
click ``The Animal Drug User Fee Cover Sheet'' and then click ``Create
ADUFA User Fee Cover Sheet.'' For security reasons, each firm
submitting an application will be assigned an organization
identification number, and each user will also be required to set up a
user account and password the first time you use this site. Online
instructions will walk you through this process.
Step Two--Create an Animal Drug User Cover Sheet, transmit it to
FDA, and print a copy. After logging into your account with your user
name and password, complete the steps required to create an Animal Drug
User Fee Cover Sheet. One cover sheet is needed for each animal drug
application or supplement. Once you are satisfied that the data on the
cover sheet is accurate and you have finalized the cover sheet, you
will be able to transmit it electronically to FDA and you will be able
to print a copy of your cover sheet showing your unique PIN.
[[Page 49669]]
Step Three--Send the payment for your application as described in
section VIII.A.
Step Four--Please submit your application and a copy of the
completed Animal Drug User Fee Cover Sheet to the following address:
Food and Drug Administration, Center for Veterinary Medicine, Document
Control Unit (HFV-199), 7500 Standish Pl., Rockville, MD 20855.
C. Product, Establishment, and Sponsor Fees
By December 31, 2016, FDA will issue invoices and payment
instructions for product, establishment, and sponsor fees for FY 2017
using this fee schedule. Payment will be due by January 31, 2017. FDA
will issue invoices in November 2017 for any products, establishments,
and sponsors subject to fees for FY 2017 that qualify for fees after
the December 2016 billing.
Dated: July 22, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-17848 Filed 7-27-16; 8:45 am]
BILLING CODE 4164-01-P